Evidence map›Paper›PMID 37917623›Full record

ArticlePloS one2023

Intranasal challenge with B. pertussis leads to more severe disease manifestations in mice than aerosol challenge.

Kelly L Weaver, Graham J Bitzer, M Allison Wolf, Gage M Pyles, Megan A DeJong, Spencer R Dublin, Annalisa B Huckaby, Maria de la Paz Gutierrez, Jesse M Hall, Ting Y Wong and 7 more

Abstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Kelly L WeaverVaccine Development Center in the Department of Microbiology, Immunology, and Cell Biology at West Virginia University, Morgantown, WV, United States of America.
Graham J BitzerVaccine Development Center in the Department of Microbiology, Immunology, and Cell Biology at West Virginia University, Morgantown, WV, United States of America.
M Allison WolfVaccine Development Center in the Department of Microbiology, Immunology, and Cell Biology at West Virginia University, Morgantown, WV, United States of America.
Gage M PylesVaccine Development Center in the Department of Microbiology, Immunology, and Cell Biology at West Virginia University, Morgantown, WV, United States of America.
Megan A DeJongVaccine Development Center in the Department of Microbiology, Immunology, and Cell Biology at West Virginia University, Morgantown, WV, United States of America.
Spencer R DublinVaccine Development Center in the Department of Microbiology, Immunology, and Cell Biology at West Virginia University, Morgantown, WV, United States of America.
Annalisa B HuckabyVaccine Development Center in the Department of Microbiology, Immunology, and Cell Biology at West Virginia University, Morgantown, WV, United States of America.
Maria de la Paz GutierrezVaccine Development Center in the Department of Microbiology, Immunology, and Cell Biology at West Virginia University, Morgantown, WV, United States of America.
Jesse M HallVaccine Development Center in the Department of Microbiology, Immunology, and Cell Biology at West Virginia University, Morgantown, WV, United States of America.
Ting Y WongVaccine Development Center in the Department of Microbiology, Immunology, and Cell Biology at West Virginia University, Morgantown, WV, United States of America.
Matthew WardenVaccine Development Center in the Department of Microbiology, Immunology, and Cell Biology at West Virginia University, Morgantown, WV, United States of America.
Jonathan E PettyVaccine Development Center in the Department of Microbiology, Immunology, and Cell Biology at West Virginia University, Morgantown, WV, United States of America.
William T WittVaccine Development Center in the Department of Microbiology, Immunology, and Cell Biology at West Virginia University, Morgantown, WV, United States of America.
Casey CunninghamVaccine Development Center in the Department of Microbiology, Immunology, and Cell Biology at West Virginia University, Morgantown, WV, United States of America.
Emel Sen-KilicVaccine Development Center in the Department of Microbiology, Immunology, and Cell Biology at West Virginia University, Morgantown, WV, United States of America.
F Heath DamronVaccine Development Center in the Department of Microbiology, Immunology, and Cell Biology at West Virginia University, Morgantown, WV, United States of America.
Mariette BarbierVaccine Development Center in the Department of Microbiology, Immunology, and Cell Biology at West Virginia University, Morgantown, WV, United States of America.ORCID 0000-0002-3250-3636

Funding

Development of mRNA-platform vaccinesR01AI153250 · NIAID · WEST VIRGINIA UNIVERSITY · PI DAMRON, FREDRICK HEATH · 2021 to 2025
$4.1M
Development of mucosal vaccines to protect against pertussisR01AI137155 · NIAID · WEST VIRGINIA UNIVERSITY · PI DAMRON, FREDRICK HEATH · 2019 to 2023
$2.9M
Vaccine Development Against Bacterial Pathogens Based on iron Acquisition ProteinsR01AI141671 · NIAID · WEST VIRGINIA UNIVERSITY · PI BARBIER, MARIETTE · 2019 to 2023
$2.5M
Cell and Molecular Biology Training Program at West Virginia UniversityT32GM133369 · NIGMS · WEST VIRGINIA UNIVERSITY · PI Zoica Cerasela Dinu, MICHAEL D SCHALLER · 2019 to 2026
$2.0M
NIAID NIH HHS R01 AI137155NIAID NIH HHS R01 AI141671NIAID NIH HHS R01 AI153250NIGMS NIH HHS T32 GM133369
6 · The paper itself

Abstract

The murine Bordetella pertussis challenge model has been utilized in preclinical research for decades. Currently, inconsistent methodologies are employed by researchers across the globe, making it difficult to compare findings. The objective of this work was to utilize the CD-1 mouse model with two routes of challenge, intranasal and aerosol administration of B. pertussis, to understand the differences in disease manifestation elicited via each route. We observed that both routes of B. pertussis challenge result in dose-dependent colonization of the respiratory tract, but overall, intranasal challenge led to higher bacterial burden in the nasal lavage, trachea, and lung. Furthermore, high dose intranasal challenge results in induction of leukocytosis and pro-inflammatory cytokine responses compared to aerosol challenge. These data highlight crucial differences in B. pertussis challenge routes that should be considered during experimental design.

Indexed as

Bordetella pertussisWhooping CoughAdministration, IntranasalAnimalsMiceMice, Inbred BALB CPertussis VaccineRespiratory Aerosols and DropletsPertussis Vaccine

Identifiers

PMID37917623
PMCPMC10621807

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.